Record Sales in March for New Zealand
PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com
FOR PUBLIC RELEASE
31 March 2025
Record Sales in March for New Zealand
Rua Bioscience (NZX: RUA) is pleased to provide the following business update, highlighting
positive sales performance across New Zealand, Australia, and Germany.
New Zealand – Record month
March marked a significant milestone in Rua’s home market, with the company achieving its
highest-ever monthly sales in New Zealand. This performance is more than a company
milestone – it’s a strong signal that Rua is not only increasing its market share, but that the
overall medicinal cannabis market is expanding.
Australia: Record Flower Sales Reflect Deepening Market Presence
Australia also delivered a record month, with Rua achieving its highest-ever unit sales of key
medicinal cannabis flower product lines. This strong result reflects the company’s consistent
presence in the Australian market, backed by growing relationships with prescribers,
distributors, and patients. Rua continues to view Australia as a strategically important growth
opportunity and is investing in strengthening its commercial footprint.
Germany: High Demand
In Germany, demand for Rua’s products remains strong. Current sales are temporarily
limited by a supply shortage to meet our increased demand, Rua expects growth to resume
as the supply chain capacity is restored over the next quarter. The German market remains a
core focus for the company’s international expansion strategy.
Rua's continued focus on quality, accessible products is resonating with patients and
prescribers alike. With new product launches planned in the coming months, Rua is well
positioned to maintain and accelerate this growth trajectory. The company is proud to be a
key player in shaping the future of medicinal cannabis in Aotearoa New Zealand.
Rua Bioscience looks forward to keeping shareholders updated as we continue this positive
growth trajectory and unlock new opportunities.
ENDS
MARKET UPDATE
PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com
The person who authorised this announcement:
Paul Naske
Chief Executive Officer
paul.naske@ruabio.com
+64 21 445154
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- NZL — New Zealand Rural Land Company Limited: FY24 Result Delivers Growth and Diversification2025-02-27
“33 New Zealand Rural Land Company LISTED ON: Rural Land Co New Zealand The Rural Land Investors New Zealand Rural Land Company Level 1, 85 Fort Street Auckland Central Auckland 1010 New Zealand +64 9 217 2905 info@nzrlc.co.nz www.nzrlc.co.nz nzrlc nzrlc…”
- AFT — AFT Pharmaceuticals Limited: AFT sees strong FY 26 as revenue reaches new record2025-05-21
“Revenue in New Zealand grew 10% to $53.8 million from $48.7 million in FY 24. Market growth was led by eyecare, pain relief, dermatology, and the broad portfolio of injectables and prescription. New Zealand operating profit improved to $8.8 million from $7.3 million in t…”
- AFT — AFT Pharmaceuticals Limited: NEW YEAR LETTER TO INVESTORS2025-01-12
“AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com maintaining control over promotional investment to improve profitability from these…”